Roivant Sciences Ltd. experienced a price increase of 3.35%, reaching a 52-week high. This movement occurs amid a broader market decline, with the Nasdaq-100 down 1.64% and the S&P 500 down 0.96%.
The surge is attributed to Roivant's announcement of significant progress in its pipeline, particularly highlighting the accelerated timelines for brepocitinib and IMVT-1402. The company plans to file a new drug application for brepocitinib in early 2026, with a potential commercial launch in early 2027. Additionally, advancements in IMVT-1402 were reported, with updated guidance for topline data in rheumatoid arthritis expected in 2026.
This positive news reflects Roivant's strategic focus on its late-stage programs, which could enhance its market position and investor confidence, despite the overall market's downward trend.
Wall Street analysts forecast ROIV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ROIV is 27.63 USD with a low forecast of 22.00 USD and a high forecast of 33.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Analyst Rating
Wall Street analysts forecast ROIV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ROIV is 27.63 USD with a low forecast of 22.00 USD and a high forecast of 33.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Buy
1 Hold
0 Sell
Strong Buy
Current: 21.910
Low
22.00
Averages
27.63
High
33.00
Current: 21.910
Low
22.00
Averages
27.63
High
33.00
Guggenheim
Buy
maintain
$25 -> $28
2025-12-18
Reason
Guggenheim
Price Target
$25 -> $28
AI Analysis
2025-12-18
maintain
Buy
Reason
Guggenheim raised the firm's price target on Roivant Sciences to $28 from $25 and keeps a Buy rating on the shares. The firm has increased its valuation for brepocitinib in dermatomyositis to $9 from $6 per share to reflect its rare disease-pricing and also made a slight adjustment of IMVT-1402 valuation across multiple indications, the analyst tells investors.
Leerink
David Risinger
maintain
$29 -> $32
2025-12-15
Reason
Leerink
David Risinger
Price Target
$29 -> $32
2025-12-15
maintain
Reason
Leerink analyst David Risinger raised the firm's price target on Roivant Sciences to $32 from $29 and keeps an Outperform rating on the shares. The firm cites higher long-term profitability following Roivant Sciences' encouraging analyst meeting on December 11.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for ROIV
Unlock Now
JPMorgan
Overweight
maintain
$26
2025-12-12
Reason
JPMorgan
Price Target
$26
2025-12-12
maintain
Overweight
Reason
JPMorgan extended Roivant Sciences as a top pick from 2025 to 2026 following the company's investor day. The firm also added Roivant to its Analyst Focus List as a growth idea. JPMorgan has an Overweight rating on the shares with a $26 price target. Roivant's business structure "should stand out on its own." the analyst tells investors in a research note. The firm says multiple catalysts" were pulled forward to 2026 across the company's core Vants.
H.C. Wainwright
Buy
maintain
$23 -> $26
2025-12-12
Reason
H.C. Wainwright
Price Target
$23 -> $26
2025-12-12
maintain
Buy
Reason
H.C. Wainwright raised the firm's price target on Roivant Sciences to $26 from $23 and keeps a Buy rating on the shares. The firm increased revenue estimates for IMVT-1402 in Graves' disease. Brepocitinib's Phase 3 win in dermatomyositis is a "game-changer" for Roivant, and the analyst meeting underscored management's plan to replicate that success, the analyst tells investors in a research note.
About ROIV
Roivant Sciences Ltd. is a biopharmaceutical company focused on improving the lives of patients by accelerating the development and commercialization of medicines that matter. The Company’s pipeline includes brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis and cutaneous sarcoidosis; IMVT-1402 and batoclimab, fully human monoclonal antibodies targeting FcRn in development across several IgG-mediated autoimmune indications; and mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
